Abstract:Background Cancer cells have the ability to activate platelets, and platelets play an important role facilitating hematogenous metastasis. One mechanism by which platelets promote metastasis is their ability to shield cancer cells from natural killer cell‐mediated death. Although much is known of how platelets affect the innate immune response, our understanding of platelet function in modulating the adaptive immune system in cancer is limited. A major negative regulator of the adaptive immune response in cancer is the immune checkpoint transmembrane protein Programmed Death Ligand 1 (PD‐L1). PD‐L1 interacts with its receptor PD on T‐cells resulting in T‐cell anergy and/or apoptosis. This cancer cell survival mechanism is exploited in various types of cancer, including lung and kidney. Interestingly, platelets upon activation secrete a number of factors that have the potential to increase cancer cell PD‐L1 expression. Therefore, we hypothesized that cancer cell‐activated platelets increase cancer cell PD‐L1 expression and that common anti‐platelet drugs inhibit this platelet‐induced up‐regulation of PD‐L1. Methods Platelets were isolated from the blood of healthy human volunteers. Human A549 lung and 786‐O renal cancer cells were incubated with and without platelets for 24 hours and cancer cell PD‐L1 surface expression was measured by flow cytometry and mRNA by qPCR. In other experiments, platelet‐cancer cell incubations were performed in the presence of anti‐platelet drugs acetylsalicylic acid (ASA – 100 mM), Prasugrel active metabolite (PAM – 10 mM) or Integrelin (10 mM). Results Platelets caused a significant increase in PD‐L1 surface expression by A549 (6.7±3.1% of A549 vs. 16.3±3.9% of A549 + platelets, P < 0.05 ) and 786‐0 cells (11.2±3.1% of 786‐O vs. 21.8±4,8% of 786‐O + platelets, P < 0.05 ). This increase in surface expression occurred as a result of a 3‐fold increase in PD‐L1 mRNA in A549 incubated with platelets. Platelets did not express PD‐L1 mRNA. Importantly, anti‐platelet drugs Prasugrel active metabolite (PAM) and Integrelin, but not acetylsalicylic acid, prevented the platelet‐dependent increase in PD‐L1 expression by A549. Conclusions Platelets up‐regulate the transcriptional expression of PD‐L1 by cancer cells, and Prasugrel and Integrelin can inhibit this up‐regulation. Further experiments are needed to determine whether platelet‐induced expression of PD‐L1 on cancer cells protects them from T‐cell induced death, and whether investigation of anti‐platelet drugs as adjuvant therapy in addition to immune checkpoint inhibitors is warranted. This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .

Inhibition of Platelet Function: Does It Offer a Chance of Better Cancer Progression Control?

The dynamic role of platelets in cancer progression and their therapeutic implications

Role of platelets in inflammation and cancer: novel therapeutic strategies

Platelet-Leukocyte Interplay in Cancer Development and Progression

Platelets and the Tumor Cell Microenvironment

Role of Platelet Activation in the Development and Metastasis of Solid Tumors

Tumor Cell-Induced Platelet Aggregation as an Emerging Therapeutic Target for Cancer Therapy

Platelet-induced inhibition of tumor cell growth.

Bidirectional Interaction Between Cancer Cells and Platelets Provides Potential Strategies for Cancer Therapies

Platelet transfusion for cancer secondary thrombocytopenia: Platelet and cancer cell interaction

Antithrombotic Agents and Cancer

Emerging roles of platelets in cancer biology and their potential as therapeutic targets

Effect of Platelets and their Pharmacological Regulation on Cancer Cell Immune Checkpoint PD‐L1 Expression

Platelets and cancer: a casual or causal relationship: revisited

Engineered Platelets for Cancer Therapy

Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin

Tumour cell-activated platelets modulate the immunological activity of CD4+, CD8+, and NK cells, which is efficiently antagonized by heparin

Platelets in the Tumor Microenvironment and Their Biological Effects on Cancer Hallmarks

Activated platelets facilitate hematogenous metastasis of breast cancer by modulating the PDGFR-β/COX-2 axis

Cancer progression and tumor hypercoagulability: a platelet perspective